Page 6 - Bioatla Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoRichard waldronMecbotamab vedotinBruce mackleOffice of orphan drug productsMd anderson cancer centerExchange commissionDepartment of thoracicLifesci advisorsBioatla incAtla presented phaseTrial dataAmerica conferenceLung cancerConditionally active biologic

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the developm.

San diegoUnited statesRichard waldronMecbotamab vedotinBruce mackleLung cancer research foundationAndrew sabin foundationLungevity foundationJohns hopkins universityCancer research prevention institute of texasExchange commissionAmerican society of clinical oncologyOffice of orphan drug productsYork university school of medicineDepartment of thoracic head neck medical oncologyMd anderson cancer center

BioAtla, Inc (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript

Operator: Good afternoon, ladies and gentlemen, and welcome to the BioAtla Third Quarter 2023 Earnings Call. At this time, all lines are in a listen-only mode.

Rick waldronSheri lydickRichard waldronBruce waldronIpsen bioscienceEric sieversKaveri pohlmanBrian chengBristol myers squibbBruce mackleHead of clinical developmentBioatla incHead of clinical development at pyxis oncologyCall transcript novemberBioatla third quarterJay short

BioAtla (NASDAQ:BCAB) Given New $10 00 Price Target at HC Wainwright

BioAtla (NASDAQ:BCAB – Get Free Report) had its price objective lowered by stock analysts at HC Wainwright from $17.00 to $10.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 468.18% […]

Jpmorgan chase coBioatla incCharles schwab investment management incSquarepoint opsTower research capitalGet free reportAtla stock downSigma advisersResearch capitalCharles schwab investment managementSchwab investment managementBioatla dailyNasdaq bcabLower price targetHc wainwright

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesRichard waldronBruce mackleMecbotamab vedotinOzuriftamab vedotinExchange commissionBioatla incLifesci advisorsOffice of orphan drug productsStage programConditionally active biologicChief executive officerPleomorphic sarcomaCell carcinomaT cell engager clinical stage